mProX™ Human RARA Stable Cell Line

Product Information

Target Protein

RARA

Target Family

Retinoic Acid Receptor

Target Protein Species

Human

Host Cell Type

AML; CHO-K1; HEK293

Target Classification

Nuclear Receptor

Target Research Area

Autoimmune Research; Cancer Research; Inflammation Research

Related Diseases

Acute Promyelocytic Leukemia; Leukemia

Gene ID

5914

UniProt ID

P10276

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

The RARA gene in humans codes for the nuclear receptor known as retinoic acid receptor alpha (RAR-α). The two nuclear receptor families that make up RXR/RAR heterodimers-retinoic acid receptor (RAR) and retinoid X receptor (RXR)-transduce retinoid signals. DNA-bound RXR/RARA recruits the corepressors NCOR1, SMRT (NCOR2), and histone deacetylase to suppress transcription in the absence of ligand. Histone acetyltransferases, coactivators, and the essential transcription machinery can be recruited when ligand attaches to the complex and causes a conformational shift. The protein known as retinoic acid receptor-alpha interacts with retinoic acid, a vitamin A derivative that is crucial for cell proliferation, differentiation, and organ creation during embryonic development. The customized RARA stable cell line can be used in antibody discovery and development, potential drug candidate screening and signaling pathway researches.

Protocols

Please visit our protocols page.

Customer Reviews

chat Amy

The RARA cell line is approximately lower than other brands of reagents and I got similar results. Nov 01 2021

chat Verified Customer

chat Sandra

I am truly impressed with the performance of this mouse RARA KD cell line and the professionalism of Creative Biolabs. I highly recommend it to anyone. Mar 03 2021

chat Verified Customer

FAQ

Any questions about our products? Please visit our frequently asked questions page.

Published Data

Fig.1 Pharicin B stabilizes RAR-α protein in AML cells.

Ref: Gu, Zhi-Min, et al. "Pharicin B stabilizes retinoic acid receptor-α and presents synergistic differentiation induction with ATRA in myeloid leukemic cells." Blood, The Journal of the American Society of Hematology 116.24 (2010): 5289-5297.

Pubmed: 20739655

DOI: 10.1182/blood-2010-02-267963

Research Highlights

Even though acute promyelocytic leukemia (APL) is one of the most well-characterized types of acute myeloid leukemia (AML), research is currently being done to determine the molecular pathways underlying the onset and course of this illness.
Liquori, Alessandro, et al. "Acute promyelocytic leukemia: a constellation of molecular events around a single PML-RARA fusion gene." Cancers 12.3 (2020): 624.
Pubmed: 32182684 DOI: 10.3390/cancers12030624

These data show that the majority of acute promyelocytic leukemia (APL) cases lacking RARA translocations also had RARB translocations, reporting a new and distinct genetic subtype of APL.
Osumi, Tomoo, et al. "Recurrent RARB translocations in acute promyelocytic leukemia lacking RARA translocation." Cancer Research 78.16 (2018): 4452-4458.
Pubmed: 29921692 DOI: 10.1158/0008-5472.CAN-18-0840